The first patient has been dosed in a global multicentre clinical trial to evaluate ISM3412, a potentially best-in-class, MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumours. The Phase I study consists of two parts: dose escalation and dose selection optimisation, where participants will receive… Read More
Researchers from Japan have shown that benzaldehyde, a compound responsible for the aroma of almonds, halts the growth and spread of therapy-resistant pancreatic cancer. By preventing various signalling proteins and histone modifiers like Ser28-phosphorylated histone H3 (H3S28ph) from binding to 14-3-3ζ protein, the study has shown that benzaldehyde overcomes therapy… Read More
DDW’s Megan Thomas attended Nebius’ inaugural AI Discovery Awards in Amsterdam, where top prizes of $100,000 in GPU credits were awarded to four companies pioneering AI breakthroughs in cancer prediction, protein targeting, transcriptomic mapping, and precision diagnostics. The winners were selected from 257 global applications by a panel of 19… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week DDW shared expert insights from the 2025 ASCO annual meeting, there… Read More
News round-up for 16-20 June by DDW Senior Digital Content Editor Diana Spencer. In the same week DDW shared expert insights from the 2025 ASCO annual meeting, there have been several significant developments in oncology drug discovery, including new therapy options for some difficult to treat cancers. Read More
This year’s American Society of Clinical Oncology (ASCO) Annual Meeting took place at the McCormick Place Convention Center in Chicago from 30 May to 3 June 2025. DDW’s Megan Thomas collected commentary from industry experts in attendance. CCR8 therapies gain clinical significance Stephan Schann is Chief Scientific Officer at Domain… Read More
This webinar, hosted by DDW and sponsored by Scale Biosciences, sees experts and thought leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. Presenters include Roy Maute, CEO and co-founder of Pheast Therapeutics,… Read More
This free webinar at 3pm BST on 12 June, hosted by DDW and sponsored by Scale Biosciences, will see experts and thought-leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. … Read More
Parabilis has achieved the first pharmacological proof-of-concept for degrading the long-considered ‘undruggable’ transcription factor ERG in prostate cancer. DDW’s Megan Thomas speaks with Dr Jonathan Hurov, Executive Vice President, Discovery Biology at Parabilis Medicines, about the milestone. MT: ERG has been considered ‘undruggable’ for decades. Why is this? JH: ERG… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Dr Emil Lou,… Read More
Scientists have obtained new data on many of the proteins responsible for regulating the cell cycle – a sequence of molecular events that culminates in the production of two daughter cells. A dysregulated cell cycle is a hallmark of several diseases, including cancer. This information will not only provide the… Read More
This free webinar at 3pm BST on 12 June, hosted by DDW and sponsored by Scale Biosciences, will see experts and thought-leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. … Read More
The START Center for Cancer Research (START) and OneOncology has announced a strategic partnership to launch early phase clinical trial sites. The rollout includes the Los Angeles Cancer Network (LACN, California), The Center for Cancer and Blood Disorders (CCBD, Texas), and Astera Cancer Care (New Jersey). This arrangement builds on… Read More
This free webinar at 3pm BST on 12 June, hosted by DDW and sponsored by Scale Biosciences, will see experts and thought-leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. … Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Phil L’Huillier, CEO of… Read More
Reece Armstrong examines the advances being made in identifying cell surface proteins and what this means for cancer drug discovery. There have been some landmark FDA approvals in recent years – but not everyone has picked up on the significance of its decision to green-light Merus’ lung and pancreatic cancer… Read More
